Leili Gao
About
Leili Gao is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Leili Gao has authored 26 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Leili Gao's work include Diabetes Treatment and Management (14 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (8 papers). Leili Gao is often cited by papers focused on Diabetes Treatment and Management (14 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (8 papers). Leili Gao collaborates with scholars based in China, United States and Philippines. Leili Gao's co-authors include Linong Ji, Wenjia Yang, Xiaoling Cai, Jing Wu, Fang Lv, Ling Chen, Xueyao Han, Qi Huang, Joshua Kim and Xiantong Zou and has published in prestigious journals such as Nature Medicine, Diabetes and Journal of Hazardous Materials.
In The Last Decade
Leili Gao
22 papers receiving 333 citations
Peers
Leili Gao
Kitirat Techatraisak Thailand
John M. Sharretts United States
Н. Г. Мокрышева Russia
Guoyu Tong China
Kazuhisa Takami Japan
Seong‐Yeon Bae South Korea
Shih‐Chen Tung Taiwan
Magdalena de la Higuera Spain
Adnan Gökçel Türkiye
Citations per year, relative to Leili Gao Leili Gao (= 1×)
peers
Kitirat Techatraisak
Countries citing papers authored by Leili Gao
Since
Specialization
Citations
This map shows the geographic impact of Leili Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leili Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leili Gao more than expected).
Fields of papers citing papers by Leili Gao
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leili Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leili Gao. The network helps show where Leili Gao may publish in the future.
Co-authorship network of co-authors of Leili Gao
This figure shows the co-authorship network connecting the top 25 collaborators of Leili Gao. A scholar is included among the top collaborators of Leili Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leili Gao. Leili Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gao, Leili, Linong Ji, Xin Yan, et al.. (2025). Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study). Diabetes Obesity and Metabolism. 27(11). 6243–6253.
2.
Yan, Li, Leili Gao, Min Xu, et al.. (2025). 745-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Obesity or Overweight (REBUILDING-1). Diabetes. 74(Supplement_1).
3.
Li, Shuyin, Leili Gao, Hongmei Song, et al.. (2024). A comprehensive atlas of multi-tissue metabolome and microbiome shifts: Exploring obesity and insulin resistance induced by perinatal bisphenol S exposure in high-fat diet-fed offspring. Journal of Hazardous Materials. 485. 136895–136895.
4.
Gao, Leili, Fang Bian, Hongwei� Jiang, et al.. (2024). Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial. Diabetes Obesity and Metabolism. 27(1). 280–290.
5.
Ji, Linong, Leili Gao, Haifang Wang, et al.. (2024). Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study. Current Medical Research and Opinion. 40(10). 1697–1703.
6.
Ji, Linong, Leili Gao, Guoliang Chen, et al.. (2024). ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study. Diabetes Therapy. 15(10). 2183–2196.
7.
Gao, Leili, Xuejun Liu, Shuchun Chen, et al.. (2023). The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross‐sectional study. Journal of Diabetes. 15(9). 765–776.
8.
Bai, Nan, Jin Wang, Leili Gao, et al.. (2023). A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China. Diabetes Therapy. 15(1). 183–199.
9.
Ji, Linong, Leili Gao, Jifang Li, et al.. (2023). A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy. Diabetes Obesity and Metabolism. 25(12). 3788–3797.
10.
Gao, Leili, Byung‐Wan Lee, Manoj Chawla, et al.. (2023). Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nature Medicine. 29(6). 1500–1510.
11.
Huang, Qi, Xiantong Zou, Yingli Chen, et al.. (2023). Personalized glucose-lowering effect of chiglitazar in type 2 diabetes. iScience. 26(11). 108195–108195.
12.
Ji, Linong, Leili Gao, Changjiang Ying, et al.. (2023). Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial. Diabetes Obesity and Metabolism. 25(12). 3671–3681.
13.
Ji, Linong, Leili Gao, Hongwei� Jiang, et al.. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 54. 101691–101691.
14.
Du, Ying, et al.. (2022). A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol. Diabetes Obesity and Metabolism. 25(3). 649–655.
15.
Gao, Leili, Zhifeng Cheng, Benli Su, et al.. (2022). Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial. Diabetes Obesity and Metabolism. 25(3). 785–795.
16.
Gao, Leili, Puhong Zhang, Jianping Weng, et al.. (2020). Patient characteristics and 6‐month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT ). Journal of Diabetes. 12(9). 668–676.
17.
Ji, Linong, Leili Gao, Liming Chen, et al.. (2020). Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE study). EClinicalMedicine. 23. 100368–100368.
18.
Lv, Fang, Xiaoling Cai, Wenjia Yang, et al.. (2019). Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 130. 115121–115121.
19.
Ren, Yanfeng, Leili Gao, Xiaohui Guo, et al.. (2018). Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China. Journal of Diabetes and its Complications. 32(11). 1000–1005.
20.
Gao, Leili, Linong Ji, Qing Su, et al.. (2015). Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study. Diabetes Research and Clinical Practice. 112. 88–93.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kitirat Techatraisak Breakdown of academic impact, for papers by John M. Sharretts Breakdown of academic impact, for papers by Н. Г. Мокрышева Breakdown of academic impact, for papers by Guoyu Tong Breakdown of academic impact, for papers by Kazuhisa Takami Breakdown of academic impact, for papers by Seong‐Yeon Bae Breakdown of academic impact, for papers by Shih‐Chen Tung Breakdown of academic impact, for papers by Magdalena de la Higuera Breakdown of academic impact, for papers by Adnan Gökçel